• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在接受静脉注射呋塞米治疗心力衰竭的患者中,口服氢氯噻嗪或静脉注射氯噻嗪联合利尿疗法效果的比较。

Comparison of the effects of combination diuretic therapy with oral hydrochlorothiazide or intravenous chlorothiazide in patients receiving intravenous furosemide therapy for the treatment of heart failure.

作者信息

Kissling Kevin T, Pickworth Kerry K

机构信息

Department of Pharmacy, The Ohio State University Wexner Medical Center, Columbus, Ohio.

出版信息

Pharmacotherapy. 2014 Aug;34(8):882-7. doi: 10.1002/phar.1456. Epub 2014 Jul 3.

DOI:10.1002/phar.1456
PMID:24990816
Abstract

STUDY OBJECTIVE

To compare the effects of combination diuretic therapy with oral hydrochlorothiazide or intravenous chlorothiazide added to background intravenous loop diuretic therapy among patients hospitalized with heart failure.

DESIGN

Single-center, retrospective review.

SETTING

Cardiovascular hospital within a university-affiliated teaching institution.

PATIENTS

Eighty-two patients hospitalized for heart failure between September 1, 2009, and August 31, 2011, who were receiving background intravenous furosemide therapy (total daily dose ≥ 160 mg); of those patients, 28 patients also received oral hydrochlorothiazide (median dose 25 mg [interquartile range 25-50 mg]), and 54 patients also received intravenous chlorothiazide (median dose 500 mg [interquartile range 250-750 mg]).

MEASUREMENTS AND MAIN RESULTS

The primary outcome was change in 24-hour urine output. Urine output was recorded from the 24 hours before and after the first administration of either oral hydrochlorothiazide or intravenous chlorothiazide. Baseline characteristics, with the exception of female sex (p=0.01) and home loop diuretic dose (p=0.03), were similar between groups. Twenty-four-hour urine output before administration of the thiazide diuretic was not significantly different between groups. After treatment, 24-hour urine output increased in both groups; however, urine output increased to a lesser extent with oral hydrochlorothiazide (from mean ± SD 2104 ± 830 ml to 3038 ± 917 ml) than with intravenous chlorothiazide (from 2342 ± 978 ml to 4128 ± 1755 ml) (p=0.005). Hypokalemia occurred frequently in both groups: 71.4% and 83.3% in the oral hydrochlorothiazide and intravenous chlorothiazide groups, respectively (p=0.21).

CONCLUSION

Among hospitalized patients with heart failure receiving intravenous loop diuretics, the addition of either oral hydrochlorothiazide or intravenous chlorothiazide augmented diuresis. Urine output increased to a greater extent with intravenous chlorothiazide compared with oral hydrochlorothiazide. However, given the positive response observed, ease of administration, and lower drug cost, oral hydrochlorothiazide should still be considered as an option for combination diuretic therapy in this patient population.

摘要

研究目的

比较在接受静脉襻利尿剂治疗的心力衰竭住院患者中,联合使用口服氢氯噻嗪或静脉注射氯噻嗪与背景静脉襻利尿剂治疗的效果。

设计

单中心回顾性研究。

地点

大学附属教学机构内的心血管医院。

患者

2009年9月1日至2011年8月31日期间因心力衰竭住院且正在接受背景静脉注射呋塞米治疗(每日总剂量≥160mg)的82例患者;其中,28例患者还接受了口服氢氯噻嗪(中位剂量25mg[四分位间距25 - 50mg]),54例患者还接受了静脉注射氯噻嗪(中位剂量500mg[四分位间距250 - 750mg])。

测量指标及主要结果

主要结局是24小时尿量的变化。在首次给予口服氢氯噻嗪或静脉注射氯噻嗪之前及之后的24小时记录尿量。除女性(p = 0.01)和家庭襻利尿剂剂量(p = 0.03)外,两组间基线特征相似。在给予噻嗪类利尿剂之前,两组间的24小时尿量无显著差异。治疗后,两组的24小时尿量均增加;然而,口服氢氯噻嗪组的尿量增加幅度(从均值±标准差2104±830ml增至3038±917ml)小于静脉注射氯噻嗪组(从2342±978ml增至4128±1755ml)(p = 0.005)。两组低钾血症均频繁发生:口服氢氯噻嗪组和静脉注射氯噻嗪组分别为71.4%和83.3%(p = 0.21)。

结论

在接受静脉襻利尿剂治疗的心力衰竭住院患者中,添加口服氢氯噻嗪或静脉注射氯噻嗪均可增强利尿作用。与口服氢氯噻嗪相比,静脉注射氯噻嗪使尿量增加幅度更大。然而,鉴于观察到的阳性反应、给药便利性及较低的药物成本,口服氢氯噻嗪仍应被视为该患者群体联合利尿剂治疗的一种选择。

相似文献

1
Comparison of the effects of combination diuretic therapy with oral hydrochlorothiazide or intravenous chlorothiazide in patients receiving intravenous furosemide therapy for the treatment of heart failure.在接受静脉注射呋塞米治疗心力衰竭的患者中,口服氢氯噻嗪或静脉注射氯噻嗪联合利尿疗法效果的比较。
Pharmacotherapy. 2014 Aug;34(8):882-7. doi: 10.1002/phar.1456. Epub 2014 Jul 3.
2
Comparison of metolazone versus chlorothiazide in acute decompensated heart failure with diuretic resistance.美托拉宗与氢氯噻嗪治疗急性失代偿性心力衰竭伴利尿剂抵抗的比较。
Cardiovasc Ther. 2015 Apr;33(2):42-9. doi: 10.1111/1755-5922.12109.
3
Efficacy and Safety of Intravenous Chlorothiazide versus Oral Metolazone in Patients with Acute Decompensated Heart Failure and Loop Diuretic Resistance.静脉注射氯噻嗪与口服美托拉宗治疗急性失代偿性心力衰竭且对袢利尿剂抵抗患者的疗效与安全性比较
Pharmacotherapy. 2016 Aug;36(8):852-60. doi: 10.1002/phar.1798. Epub 2016 Jul 29.
4
Intravenous Chlorothiazide Versus Enteral Metolazone to Augment Loop Diuretic Therapy in the Intensive Care Unit.静脉注射氯噻嗪与口服美托拉宗用于加强重症监护病房的袢利尿剂治疗
Ann Pharmacother. 2017 Apr;51(4):286-292. doi: 10.1177/1060028016683971. Epub 2016 Dec 16.
5
Efficacy of Intravenous Chlorothiazide for Refractory Acute Decompensated Heart Failure Unresponsive to Adjunct Metolazone.静脉注射氯噻嗪治疗对辅助使用美托拉宗无反应的难治性急性失代偿性心力衰竭的疗效。
Pharmacotherapy. 2016 Aug;36(8):843-51. doi: 10.1002/phar.1787. Epub 2016 Jul 21.
6
Diuretic Strategies for Loop Diuretic Resistance in Acute Heart Failure: The 3T Trial.利尿剂策略治疗急性心力衰竭中袢利尿剂抵抗:3T 试验。
JACC Heart Fail. 2020 Mar;8(3):157-168. doi: 10.1016/j.jchf.2019.09.012. Epub 2019 Dec 11.
7
In chronic heart failure with marked fluid retention, the i.v. high doses of loop diuretic are a predictor of aggravated renal dysfunction, especially in the set of heart failure with normal or only mildly impaired left ventricular systolic function.在伴有明显液体潴留的慢性心力衰竭中,静脉注射大剂量袢利尿剂是肾功能恶化的一个预测指标,尤其是在左心室收缩功能正常或仅轻度受损的心力衰竭患者中。
Minerva Cardioangiol. 2011 Dec;59(6):543-54. Epub 2011 Feb 18.
8
Combining Loop and Thiazide Diuretics Across the Left Ventricular Ejection Fraction Spectrum: The CLOROTIC Trial.跨左心室射血分数范围联合使用襻利尿剂和噻嗪类利尿剂:CLOROTIC试验
JACC Heart Fail. 2024 Oct;12(10):1719-1730. doi: 10.1016/j.jchf.2024.05.006. Epub 2024 Jun 26.
9
Metolazone Versus Chlorothiazide in Acute Heart Failure Patients With Diuretic Resistance and Renal Dysfunction: A Retrospective Cohort Study.美托拉宗与氯噻嗪在利尿剂抵抗和肾功能障碍的急性心力衰竭患者中的比较:一项回顾性队列研究。
J Cardiovasc Pharmacol. 2024 Oct 1;84(4):451-456. doi: 10.1097/FJC.0000000000001623.
10
Effects of high-dose furosemide and small-volume hypertonic saline solution infusion in comparison with a high dose of furosemide as bolus in refractory congestive heart failure: long-term effects.大剂量呋塞米与小容量高渗盐溶液输注对比大剂量呋塞米推注治疗难治性充血性心力衰竭的长期效果
Am Heart J. 2003 Mar;145(3):459-66. doi: 10.1067/mhj.2003.166.

引用本文的文献

1
The Effect of the AQP1 Gene Knockout on the Diversity, Composition and Function of Gut Microbiota in Mice with Heart Failure.水通道蛋白1基因敲除对心力衰竭小鼠肠道微生物群多样性、组成及功能的影响
Biology (Basel). 2025 Jul 4;14(7):815. doi: 10.3390/biology14070815.
2
Diuretics: a review of the pharmacology and effects on glucose homeostasis.利尿剂:药理学及其对葡萄糖稳态影响的综述
Front Pharmacol. 2025 Mar 28;16:1513125. doi: 10.3389/fphar.2025.1513125. eCollection 2025.
3
Combination Diuretic Therapy With Thiazides: A Systematic Review on the Beneficial Approach to Overcome Refractory Fluid Overload in Heart Failure.
噻嗪类联合利尿剂治疗:克服心力衰竭难治性液体超负荷的有益方法的系统评价
Cureus. 2023 Sep 3;15(9):e44624. doi: 10.7759/cureus.44624. eCollection 2023 Sep.
4
Pathophysiology of Diuretic Resistance and Its Implications for the Management of Chronic Heart Failure.利尿剂抵抗的病理生理学及其对慢性心力衰竭治疗的影响。
Hypertension. 2020 Oct;76(4):1045-1054. doi: 10.1161/HYPERTENSIONAHA.120.15205. Epub 2020 Aug 24.
5
Diuretic Strategies for Loop Diuretic Resistance in Acute Heart Failure: The 3T Trial.利尿剂策略治疗急性心力衰竭中袢利尿剂抵抗:3T 试验。
JACC Heart Fail. 2020 Mar;8(3):157-168. doi: 10.1016/j.jchf.2019.09.012. Epub 2019 Dec 11.
6
Loop diuretic resistance complicating acute heart failure.利尿剂抵抗合并急性心力衰竭。
Heart Fail Rev. 2020 Jan;25(1):133-145. doi: 10.1007/s10741-019-09851-9.